Bien que la plupart des études se focalisent sur les lymphocytes T CD4+ régulateurs, il a été observé que les lymphocytes T CD8+ régulateurs peuvent jouer un rôle important dans l’induction et le maintien de la tolérance immunitaire. Le transfert adoptif chez la souris et l’induction chez l’homme de lymphocytes T CD8+ régulateurs peuvent inhiber le rejet d’allogreffes et le développement de pathologies autoimmunes. Ces observations suggèrent que l’induction de ces populations peut avoir un potentiel thérapeutique. Des études supplémentaires sont encore nécessaires pour définir les conditions optimales de leur induction. <p>Tant les nouveaux nés humains que murins ont une plus forte capacité que l’adulte à développer des lymphocytes T CD4+ régulateurs induits par une reconnaissance antigénique. La période néonatale serait donc particulièrement appropriée à l’induction de circuits régulateurs.<p>Dans le cadre de ce travail, nous avons étudié le rôle des lymphocytes T CD8+, induits à la naissance, dans le contrôle de la réponse des lymphocytes T CD4+ de type Th2.<p>Des souris BALB/c sont immunisées à la naissance à l’aide de cellules spléniques semi-allogéniques hybrides F1 (AJAX x BALB/c). Ces cellules persistent dans l’animal, au sein des organes lymphoïdes et stimulent ainsi de manière chronique les lymphocytes T CD4+ et T CD8+ du receveur et induisent une réponse de type Th2. Suite à l’injection des cellules spléniques semi-allogéniques au nouveau né de souris, nous avons observé l’expansion d’une population de lymphocytes T CD8+CD25+, dont le phénotype se caractérise par l’expression de Foxp3 et la production conjointe d’IFN-&61543; et l’IL-10. Nous avons pu observer que ces cellules sont capables d’inhiber la production de cytokines Th2 produites par les lymphocytes T CD4+ allospécifiques activés. Par contre, ces cellules régulatrices aggravent des réponses Th2 non apparentées. En effet, suite à une sensibilisation à l’ovalbumine, à l’âge adulte, ces souris développent de plus fortes réponses asthmatiques.<p>D’autre part, les nouveaux nés de souris BALB/c ont été immunisés à la naissance à l’aide de cellules dendritiques semi-allogéniques hybrides F1 (AJAX x BALB/c) qui activent de manière aigüe leurs lymphocytes T. Ces souris présentent une forte réponse Th1 et Tc1/Tc2 spécifique de l’alloantigène et sont protégées contre le développement d’un asthme induit. Il a aussi été montré dans ce travail que suite à l’immunisation néonatale à l’aide de cellules dendritiques semi-allogéniques, le nombre de lymphocytes T CD8+CD44high, CD8+CD62Lhigh et CD8+CD25+ producteurs d’IFN-&61543; augmente significativement. L’IFN-& / Doctorat en Sciences biomédicales et pharmaceutiques / info:eu-repo/semantics/nonPublished

Le système immunitaire nous protège contre les infections et les cancers. Cependant, des réponses immunitaires excessives ou incontrôlées peuvent causer des pathologies potentiellement mortelles comme le choc endotoxinique, des maladies auto-immunes, ou le rejet d’allogreffe. Une compréhension claire des mécanismes de régulation des réponses immunes permettrait d’envisager de nouvelles thérapeutiques plus ciblées. Dans ce travail réalisé chez la souris, la modulation de la réponse inflammatoire à une toxine bactérienne, le lipopolysaccharide (LPS), a été utilisée comme archétype de la régulation immunitaire. Ceci nous a permis de démontrer que la régulation de la prolifération homéostatique de lymphocytes T CD4+CD25- par des lymphocytes T régulateurs naturels tempère la réponse inflammatoire au LPS. Cet effet est notamment dépendant d’une diminution de la sécrétion d’IFN-γ par les lymphocytes activés par la prolifération induite par la lymphopénie. Nous avons aussi observé, que la désensibilisation du système immunitaire inné vis-à-vis du LPS, suite à des injections répétées d’endotoxine, induit le développement de cellules myéloïdes suppressives (myeloïd-derived suppressor cells MDSC) capables de réguler des réponses lymphocytaires T in vitro et in vivo. Nous avons pu mettre en évidence que l’effet suppresseur des MDSC est dépendant de leur expression de l’enzyme hème oxygénase-1 et de leur production d’IL-10. Le dialogue constant entre les cellules de l’immunité innée et de l’immunité acquise assure donc à la fois l’activation et la régulation du système immunitaire. Dans la majorité des cas, ceci permet aux réponses immunitaires d’être efficaces sans être excessives. La mise en évidence de ces processus identifie les lymphocytes T régulateurs et les cellules myéloïdes suppressives comme des éléments clefs de la régulation d’un processus inflammatoire. Les traitements immunosuppresseurs, les thérapies cellulaires et les greffes de moelle ont des effets variables et mal connu sur ces populations de cellules régulatrices. Tenir compte de ces interférences thérapeutiques avec les processus naturels de régulation de notre système immunitaire permettra certainement d’optimaliser l’utilisation de ce type de traitements. D’autre part, l’utilisation thérapeutique de ces deux types de cellules régulatrices pourrait être envisagé dans de nouvelles stratégies d’immuno-modulation plus « physiologique ».<p> / Doctorat en Sciences médicales / info:eu-repo/semantics/nonPublished

The failure of the immune system to provide efficient protection against tumour cells has been considered as a major issue in immunology. It is now well established that inadequate function of the host immune system is one of the main mechanisms by which tumours escape from immune control contributing to the limited success of cancer immunotherapy. Several cell populations have been described which display immunosuppressive properties and may impede tumor-specific immunity. Among them, GR1+CD11b+ immature myeloid suppressor cells and CD4+CD25+ regulatory T cells seem to play an important role. These cells accumulate in the spleens of tumour bearing mice and patients with cancer and contribute to immunosuppression by inhibiting the function of CD8+ T cells and/or by promoting tumour angiogenesis.<p><p>The aim of our work was to define the mechanisms by which a single dose of cyclophosphamide (CTX), a chemical agent commonly used in chemotherapy treatment, induces the rejection of established P815 mastocytoma. <p><p>Our data show that CTX treatment leads to the selective loss of GR1medCD11b+ splenic myeloid cell producing TGF-â, a cytokine which is known to suppress antitumoral response. Furthermore, injection of CTX causes a decrease in the number of naturally occurring regulatory T cells (CD4+CD25+Foxp3+) in the spleen and the tumor. Finally, CTX treatment induces the differentiation of GR1highCD11b+ splenic myeloid cells into mature GR1highCD11b+CD11c+ (possibly dendritic cells?) which express high levels of CD11c, MHC class II and CD86 molecules. Of note, these cells are mainly detected in tumour necrosis areas. <p><p>Collectively, these results suggest that CTX prevents suppressive mechanisms and induces a population of CD11c+ myeloid cells which may present tumor antigens and activate T lymphocytes, an hypothesis in line with the requirement for CD4+ cells in CTX-induced long term resistance. <p> / Doctorat en Sciences / info:eu-repo/semantics/nonPublished

Le microenvironnement tumoral et les cellules et molécules signal (cytokines et chimiokines) qu’ils contiennent sont reconnus comme jouant un rôle prépondérant dans la progression des tumeurs. Il devient donc nécessaire d’étudier la relation entre les molécules signal, les cellules infiltrantes et les cellules tumorales. Le TGF-β est une puissante cytokine immunosuppressive et suppressive de la croissance cellulaire, dont le rôle dans la formation du microenvironnement tumoral leucémique est mal connu. Dans cette étude, nous avons étudié le modèle injectable de leucémie lymphoïde T EL4 (cellules tumorales produisant du TGF-β) de souche C57BL/6. Nous avons caractérisé l’infiltration de cellules myéloïdes et lymphoïdes au niveau des tumeurs par cytométrie en flux et par microscopie à fluorescence. L’analyse des cellules infiltrant les tumeurs EL4 nous a permis de montrer la forte présence de lymphocytes T et de cellules myéloïdes CD11b+. Nous avons donc poursuivi l’étude afin de mieux caractériser ces cellules. Nous avons montré que ces cellules se retrouvent en périphérie de la tumeur et en périphérie des vaisseaux sanguins de la tumeur. Ces cellules ont des phénotypes nous laissant croire qu’elles appartiennent à la famille des cellules dite myéloïdes suppressives. Ces cellules ont de forts niveaux de transcrits de VEGF et de MMP9 au niveau de la tumeur ainsi qu’au niveau systémique, mais ne semblent pas avoir une forte capacité inhibitrice in vitro. Afin de déterminer si la production tumorale de TGF-β influe le recrutement de ces cellules, nous avons transformé des cellules EL4 à l’aide d’un shRNA afin de diminuer la production de TGF-β (shRNA-TGF-β) et, comparé l’infiltration myéloïde et lymphoïde de tumeurs formées avec des cellules EL4 contrôles (shRNA-Luc). Une diminution de 50% dans les niveaux de transcrits de TGF-β n’affecte pas la croissance tumorale mais semble diminuer l’infiltration par des cellules myéloïdes. La présente étude nous a permis de mieux comprendre le modèle de leucémie EL4 et le rôle des populations cellulaires myéloïdes dans le microenvironnement tumoral leucémique. La diminution du TGF-β produit par les cellules tumorales réduit l’infiltration de ces populations myéloïdes dans la tumeur EL4. Le rôle précis de ces cellules est encore à déterminer. Ces résultats sont en accord avec le fait qu’une thérapie anti-TGF-β n’est pas suffisante pour contrer la progression tumorale, mais pourrait influer sur le résultat post-chimiothérapie et l’immunothérapie en altérant la composition du microenvironnement. / The cells and signal molecules (cytokines and chemokines) making up the tumoral microenvironnement are known to play an essential role in tumor progression. It seems to be necessary to study the relationship between infiltrating cells, tumor cells and signal molecules. TGF-β is a potent immunosuppressive and growth suppressive cytokine whose role in the formation of the leukemia microenvironnement remains unclear. In this study, we investigated the injectable T lymphocyte leukemia EL4 model (tumor cells producing TGF-β) of C57BL/6 strain. We characterised the myeloid and lymphoid infiltration in EL4 tumors using flow cytometry and fluorescence microscopy. Our analysis of EL4 tumor infiltrating cells showed a high concentration of T lymphocytes and myeloid cells CD11b+. We have undertaken our study to better characterize these cells. We showed that these cells are present at the periphery of the tumor and are surrounding blood vessels in the tumor. These cells have phenotypes leading us to believe that they belong to the family of so-called myeloid suppressor cells. They have high levels of transcripts of VEGF and MMP9 in the tumor and the systemic level, but do not seem to have a strong inhibitory capacity in vitro. To determine whether the tumor production of TGF-β affects the recruitment of these cells, we transformed EL4 cells using a shRNA to reduce the production of TGF-β (TGF-β shRNA ) and compared the myeloid and lymphoid infiltration of tumors formed with EL4 cell controls ( shRNA-Luc ) . A 50% decrease in transcript levels of TGF-β does not affect tumor growth but appears to decrease infiltration by myeloid cells. This study allowed us to better understand the pattern of EL4 leukemia and the role of myeloid leukemia cell populations in the tumor microenvironment. The decrease of TGF-β produced by tumor cells reduces the infiltration of these myeloid populations within the EL4 tumor. The precise role of these cells still needs to be determined. These results are in agreement with the fact that anti-TGF-β therapy is not sufficient to counteract tumor progression, but may affect the post-chemotherapy and immunotherapy results by altering the composition of the microenvironment.

The boy-to-girl ratio at birth (secondary sex ratio) is around 1.06 in most populations. The sex ratio may be influenced by many factors, such as stress and immunosuppression, age of parents, parity and sex of preceding siblings. The most common human protozoan parasite in developed countries, Toxoplasma gondii (prevalence 20% - 80%), is known to change the behaviour of its intermediate hosts, thereby increasing the probability of transmission to its definitive host (the cat) by predation. The results of our retrospective cohort study suggest that the presence of Toxoplasma gondii, can influence the secondary sex ratio in humans. Depending on the antibody concentration, the probability of the birth of a boy can increase up to a value of 0.72, which means that for every 260 boys born, 100 girls are born to women with the highest concentration of anti-Toxoplasma antibodies. In accordance with results on human subjects, laboratory mice with toxoplasmosis produced a higher sex ratio than controls, in the early phase of latent infection. Our further results showed that mice in the early phase of latent infection exhibited temporarily increased production of interleukin (IL)-12 and decreased production of IL-10. The mice showed decreased production of IL-2 and nitric oxide and decreased proliferation...

Introdução: Indivíduos sobreviventes à sepse apresentam maior mortalidade à longo prazo e maior risco de apresentar infecções oportunistas. Existem evidências clínicas e experimentais de desregulação imune no estado pós-sepse. Essas alterações apresentam semelhança com aquelas encontradas no microambiente tumoral, estando relacionadas à imunossupressão. O presente trabalho avaliou o papel de macrófagos associados ao tumor (TAM) em modelo de progressão tumoral em camundongos sobreviventes à sepse. Materiais e Métodos: Camundongos C57/BL6 foram submetidos a ligadura e punção cecal (CLP) e tratados com ertapenem (20 mg/kg, i.p., 6 horas após CLP e 12/12 h por 3 dias). Os animais sobreviventes de sepse eram inoculados com células de melanoma B16-F10 (30 mil, s.c., 15 dias após a CLP). Animais naïve foram usados como controle. Foram avaliadas a progressão tumoral, sobrevida e formação de metástases espontâneas à distância. No D+14, animais foram sacrificados para mensuração do acúmulo de TAM por citometria de fluxo (CD45+F4/80+CD206+) e de citocinas no soro e no tumor por ELISA (IFN-?, IL-10, TNF-?, TGF-?, CCL2, CXCL12). Macrófagos derivados de medula óssea de animais pós-CLP ou naïve foram coinoculados com células B16 para avaliação de progressão tumoral e sobrevida. TAM de animais naïve ou pós-CLP foram isolados através de gradiente de Percoll seguido de adesão seletiva e o RNA foi isolado para análise diferencial de expressão gênica por microarray. Para avaliação da participação da via CXCL12/CXCR4 foi realizada sua inibição com o AMD3100, antagonista de CXCR4 (5 mg/kg, i.p., D+10 e D+14). Foi avaliada a progressão tumoral, sobrevida, acúmulo de TAM e proliferação extramedular de TAM no D+14. Resultados: Animais sobreviventes de sepse apresentaram aumento de progressão tumoral (após 15, 30 e 60 dias da CLP), aumento da carga de metástases (após 15 dias da CLP) e redução de sobrevida. Foi detectado o aumento de TAM nos animais pós-CLP, associado a maior marcação de Ki67, em comparação com animais naïve no D+14. Verificamos aumento das concentrações séricas de TGF-?, CXCL12, CCL2 e TNF-?. Camundongos naïve que coinoculados com macrófagos derivados de medula óssea de animais pós-CLP apresentaram aumento de progressão tumoral e redução de sobrevida em comparação com o grupo controle. TAM de animais pós-CLP apresentaram menor expressão de genes relacionados ao MHC-II e genes relacionados à ativação leucocitária. A inibição de CXCL12/CXCR4 preveniu a progressão tumoral induzida por sepse, com menor acúmulo de TAM e menor presença de TAM Ki67+. Conclusões: O estado pós-sepse promove a progressão tumoral de melanoma B16 em camundongos, o qual foi associado a aumento de 12 TAM. A via CXCL12/CXCR4 participa do processo de acúmulo de TAM nesse modelo experimental. / Background: Survivors from sepsis present higher long-term mortality and increased risk of opportunistic infections. There is clinical and experimental evidence for an immunosuppressive immune dysregulation in post-sepsis. These alterations are similar to those found in tumor microenvironment. The present work assessed the role of tumorassociated macrophage (TAM) in a model of tumor progression in sepsis-surviving mice. Materials and Methods: C57/BL6 mice were submitted to cecal ligation and puncture (CLP) and treated with ertapenem (20 mg/kg, ip. - 6 h after CLP and then each 12 h for 3 days). Sepsis surviving mice were inoculated with B16-F10 melanoma cells (30,000, sc., 15 days after CLP). Naïve mice were used as controls. Tumor progression, survival and distant spontaneous metastasis were evaluated. Mice were killed at D+14 for TAM measurement through flow cytometry (CD45+F4/80+CD206+) and for cytokines (IFN-?, IL-10, TNF-?, TGF-?, CCL2, CXCL12) quantification by ELISA. Bone marrow-derived macrophage (BMDM) were isolated and co-inoculated together with B16 melanoma cells for tumor progression and survival evaluation. TAM from naïve or post-sepsis mice were isolated through Percoll gradient (70/30) followed by selective adhesion. The RNA was isolated for gene expression analysis using microarray assay. To evaluate the role of CXCL12/CXCR4, we used the specific antagonist AMD3100 (5 mg/kg, ip., at D+10 and D+14) and assessed tumor progression, survival and TAM accumulation at D+14. Results: Sepsis-surviving mice showed increased tumor progression (15, 30 or 60 days after CLP), higher metastatic burden (15 days after CLP), and less overall survival. TAM were increased in post-sepsis mice at D+14. We found increased serum levels of TGF-?, CXCL12, CCL2 e TNF-?. Naïve mice inoculated with BMDM from post-sepsis and B16 cells showed higher tumoral progression and less survival, when compared to the control group. TAM from post-sepsis showed decreased expression of MHC-II related genes and genes related to leukocyte activation. The inhibition of CXCL12/CXCR4 prevented the post-sepsis-induced tumor progression, with less TAM accumulation and reduced expression of Ki67 in TAM. Conclusions: The post-sepsis state promotes the progression of B16 melanoma in mice, which was associated with an increase in TAM accumulation. CXCL12/CXCR4 mediates TAM accumulation in this experimental model.

Contexto: O tratamento da hepatite autoimune (HAI) composto por prednisona e azatioprina proporciona melhora clínico-laboratorial em até 90% dos pacientes. Entretanto, a remissão completa não é alcançável na maioria dos casos. Cloroquina é um antimalárico utilizado no tratamento de doenças reumatológicas autoimunes e em estudo aberto de manutenção da remissão da HAI foi sugerido menor risco de recidiva da doença com o uso da droga. Objetivos: Avaliar o uso da cloroquina em associação à prednisona no tratamento da HAI em estudo randomizado. Métodos: 57 pacientes com indicação de tratamento da HAI foram randomizados para receber azatioprina ou cloroquina associadas à prednisona, de 2003 a 2012. Para os que mantiveram normalização das transaminases por 18 meses, biópsia hepática foi realizada para avaliação histológica. O desfecho primário foi a remissão completa ao tratamento, composta por remissão bioquímica e histológica da doença. O valor de p < 0,05 foi considerado estatisticamente significativo. Resultados: Não houve diferença entre os grupos quanto às características clínicas, sorológicas, histológicas e de tratamento prévio, ao início do estudo. A idade média foi de 37,2 ± 16,84 anos, 43,8% com fibrose avançada (F3/4) no início do estudo. Não houve diferença estatística na taxa de resposta bioquímica (67% vs. 53,8%, p=0,413) ou histológica (32,2% vs. 15,4%, p=0,21), assim como na dose média de prednisona utilizada. Os pacientes que não atingiram remissão completa no estudo tiveram seguimento com nova terapia. Entre eles, quatro obtiveram remissão histológica com a associação de azatioprina, cloroquina e prednisona. Em relação aos efeitos adversos, houve maior taxa no grupo da cloroquina, porém com tendência a menor prevalência de comorbidades neste grupo. Conclusão: Quando bem toleradas, cloroquina e prednisona proporcionaram resposta completa em pacientes com AIH, sem diferença estatística em relação à terapia padrão. (ClinicalTrials.gov NCT 02463331) / Background: The treatment of autoimmune hepatitis (AIH) with prednisone and azathioprine provides disease remission. However, a complete biochemical and histological response is unreachable in most patients. Chloroquine is an antimalarial drug used for treating rheumatological diseases. It was studied as a single drug for the maintenance of AIH remission in an open study, which suggested a lower risk of relapse in the chloroquine group. Aims: To evaluate a possible role of chloroquine and prednisone for AIH treatment in a randomized study. Methods: 57 AIH adult patients with indication of treatment were enrolled to receive azathioprine or chloroquine, both with varying doses of prednisone, from 2003 to 2012. For those who had maintained biochemical remission for 18 months, liver biopsy was performed to evaluate histological remission. The primary outcome was the achievement of complete response to treatment. A p-value < 0.05 was considered statistically significant. Results: There were no significant differences between the groups concerning clinical, serological, histological, and treatment features at baseline. The average age was 37.2 ± 16.84 years, 43.8% with advanced fibrosis (F3/4) at baseline. There was no statistical differences in biochemical (67.7% vs. 53.8%, p=0.41) or histological response rate (32.26% vs. 15.38%, p = 0.217), as well as in the mean prednisone dose. There was a higher rate of adverse effects in the chloroquine group, but a lower frequency of comorbidities in this group. Conclusion: When well tolerated, chloroquine with prednisone provided a complete therapeutic response in AIH patients with no statistical difference when compared to the standard treatment. (ClinicalTrials.gov NCT 02463331)

Seit vielen Jahren werden Glukokortikoide routinemäßig eingesetzt, um Zeichen der inflammatorischen Reaktion nach kardiochirurgischen Eingriffen unter extrakorporaler Zirkulation (EKZ) zu mildern. Glukokortikoide sind jedoch für ihre immunsuppressiven Wirkungen bekannt, und bisher blieben die möglichen Auswirkungen auf immunologische Funktionen weitgehend hypothetisch. Ziel der vorliegenden Studie war es daher, den Einfluss von Methylprednisolon (MP) und Tirilazad Mesylat (TM), einer antiinflammatorischen Substanz aus der Klasse der Aminosteroide auf immunologische Funktionen nach koronarchirurgischen Eingriffen mit EKZ zu untersuchen. 38 Patienten wurden randomisiert den Behandlungsgruppen Placebo (NaCl 0,9 %, n=13), MP (15 mg/ kg KG, n=12) und TM (10 mg/kg KG, n=13) zugeteilt. Die Verläufe der Plasmakonzentrationen von IL-6 und IL-10, der monozytären HLA-DR Expression und der ex vivo LPS-stimulierten TNF-alpha, IL-1RA, IFN-gamma und IL-12 Sekretion wurden bestimmt. Im Vergleich zu Placebo resultierte die Gabe von MP in geringeren postoperativen Plasmakonzentrationen von IL-6, aber einer deutlichen Erhöhung von IL-10. Die monozytäre HLA-DR Expression nahm postoperativ in allen Gruppen ab mit einer deutlichen Verstärkung durch MP. Die ex vivo stimulierte TNF-alpha Sekretion nahm postoperativ in allen Gruppen deutlich ab, ebenfalls mit einer deutlichen Verstärkung durch MP. Die IL-1RA Sekretion hingegen war zu keinem Zeitpunkt eingeschränkt. Die ex vivo stimulierte IFN-gamma und IL-12 war postoperativ in allen Gruppen stark vermindert ohne Einfluss einer medikamentösen Behandlung. Die Gabe von TM zeigte keinerlei Beeinflussung aller gemessenen Parameter im Vergleich zu Placebo. Nach koronarchirurgischen Eingriffen sind insbesondere monozytäre Funktionen stark eingeschränkt. Diese Suppression wird durch die Gabe von MP verstärkt, während die Gabe von TM nicht in einer zusätzlichen Immunsuppression resultiert. IL-10 scheint eine Schlüsselrolle bei der beobachteten monozytären Funktionseinschränkung einzunehmen. / Glucocorticoids have been routinely applied in cardiac surgery involving cardiopulmonary bypass (CPB) for many years in order to diminish inflammatory stress reactions. On the other hand glucocorticoids are well known for their immunosuppressive effects, and data on the consequences on immune function are scarce. Thus it was the aim of this trial to determine the influence of methylprednisolone (MP) and tirilazad mesylate (TM), an antiinflammatory drug of the class of aminosteroids, on immunological parameters after coronary surgery involving CPB. 38 patients were randomised to receive either placebo (NaCl 0.9 %, n=13), MP (15 mg/kg, n=12) or TM (10 mg/kg, n=13) treatment. Plasma concentrations of IL-6 and IL-10, monocyte surface expression of HLA-DR and the ex vivo endotoxin-stimulated secretion of TNF-alpha, IL-1RA, IFN-gamma und IL-12 were measured. Compared to placebo IL-6 concentrations were lower after MP treatment, whereas IL-10 levels were much higher. The rate of HLA-DR+-monocytes decreased in all groups with a significant aggravation by MP treatment. The ex vivo stimulated TNF-alpha secretion was postoperatively diminished in all groups, with again significantly lower values after MP treatment. IL-1RA secretion was not suppressed at any point. The ex vivo stimulated IFN-gamma and IL-12 secretion was strongly suppressed postoperatively regardless of the treatment. TM treatment resulted in no alterations of any parameter measured. It was demonstrated that especially monocyte functions are depressed after coronary surgery, and that MP treatment results in marked aggravation of this immunosuppression, whereas TM treatment shows no additional immunosuppressive effect. IL-10 seems to play a key role in the observed monocyte functional depression.

As células dendríticas (DCs) são as principais células apresentadoras de antígeno do sistema imune, e há evidências da participação na tolerância imunológica. Neste estudo avaliamos as alterações ocorridas na população de células CD4+CD25+Foxp3+ após co-cultura de células de linfonodo com BMDCs, na presença de timócitos alogênicos ou singênicos em apoptose. Após cultura na presença de células alogênicas a população de Tregs mostra-se aumentada, e essa expansão é dependente de contato entre a DC e o linfócito T, já que o isolamento das culturas diminuiu a expressão destes marcadores. A internalização de células em apoptose foi induziu caráter tolerogênico nas DCs com baixa expressão de moléculas co-estimuladoras e resistência à maturação por LPS. As células CD4+CD25+ geradas in vitro foram capazes de conter a proliferação de esplenócitos de camundongos BALB/c estimulados por esplenócitos de C57BL/6 irradiados, anti-CD3 e OVA. No ensaio in vivo, as Tregs geradas in vitro também foram capazes de suprimir a proliferação de células CD25- quando transferidas para animais Nude, impedindo também o infiltrado inflamatório no estômago, cólon, fígado e rins, sendo assim capazes de suprimir a resposta imune in vitro e in vivo. / The dendritic cell (DC) plays a very important role in antigen presentation in the immune system and recent articles have shown the involvement in maintaining peripheral tolerance. Here we evaluated the changes in the CD4+CD25+Foxp3+ after co culture of DCs with lymph node cells. BMDCs were pulsed with apoptotic cells and co-cultured with lymph-node cells. Our results show an increase of CD4+CD25+Foxp3+ T cells after co-culture with DCs pulsed with apoptotic cells. Furthermore, the DCs did not change the pattern of co-stimulatory molecules expression due to phagocytosis of syngeneic or allogeneic apoptotic cells and further stimulation with LPS. The CD4+CD25+ cells sorted from the in vitro culture were able to suppress the proliferation of splenocytes in vitro in a specific and non-specific manner. As expected, the co-transfer of CD4+CD25- and CD4+CD25+, both sorted from the in vitro culture, was able to control the cell infiltrates in the target organs and the total cell count in the lymph-nodes. Thus, the Tregs expanded in vitro are able to suppress the immune response in vitro and in vivo assays.

O veneno da subespécie de cascavel Crotalus durissus terrificus (C.d.terrificus) altera a coagulação, tem ação neurotóxica, miotóxica e efeito imunossupressivo. O veneno de C.d.terrificus e a sua fração majoritária, crotoxina (CTX), inibem a resposta celular e humoral, sendo esse efeito independente da indução de morte celular. O objetivo foi investigar os mecanismos envolvidos na imunossupressão exercida pela CTX. A CTX induz a produção de IL-10, TGF-<font face=\"Symbol\">&#946 e prostaglandina E2 (PGE2) pelas células dos camundongos que a receberam. Menor secreção de IFN-<font face=\"Symbol\">&#947 e IL-12 foi observada nas culturas de células de camundongos imunizados e que receberam CTX. A CTX aumenta a expressão da enzima indoleamina 2,3 dioxigenase e a geração de células T reguladoras em camundongos imunizados com OVA e que receberam CTX. A CTX foi capaz de inibir a expressão de CD40, CD80, CD86 e de MHC de classe II em células de camundongos imunizados e nas células dendríticas (DCs) purificadas destes animais. Em culturas de DCs, a CTX induz alta secreção de IL-10, TGF-<font face=\"Symbol\">&#946 e PGE2 e menor de IL-12. / The venom of the rattlesnake Crotalus durissus terrificus (C.d.terrificus) changes the coagulation system and presents neurotoxic, myotoxic and immunosuppressive effect. The venom and its main fraction, crotoxin (CTX) inhibited both the cellular and humoral response. This effect is not due to induction of cell death. The objective was to investigate the immunosuppressive mechanisms of CTX. CTX induces production of IL-10, TGF-<font face=\"Symbol\">&#946 and prostaglandin E2 (PGE2) by cells of mice that received it. Lower secretion of IFN-<font face=\"Symbol\">&#947 and IL-12 was observed in the cultured cells from mice immunized that received CTX. CTX promotes increased expression of the enzyme indoleamine 2,3 dioxygenase and generation of regulatory T cells in mice immunized with OVA and receiving the toxin. CTX was able to inhibit the expression of CD40, CD80, CD86 and MHC II in mice immunized and in dendritic cells (DCs) purified from these animals. In cultures of DCs, CTX increased secretion of IL-10, TGF-<font face=\"Symbol\">&#946 and PGE 2 and lower IL-12.